A Germany-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage as well as unmet needs are also discussed. Key pipeline assets highlighted include Nidlegy, Libtayo/fianlimab, mRNA-4157, naporafenib, and TAVO. 

This interview was conducted on 26 February 2024. 

If you are a KOL Insight Subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.